Table 2.
Immunotoxins tested for sarcoma therapy.
| Target | Antibody | Toxin | Tumor | In Vitro | In Vivo | Clinical Trial | Ref. |
|---|---|---|---|---|---|---|---|
| CSPG4 | αMCSP | ETA’ | RMS | √ | - | - | [82] |
| EGFR | 425 (scFv) | ETA’ | RMS | √ | - | - | [86] |
| murine mAb (clone 528) | Saporin | RMS | √ | - | - | [87] | |
| gp72 | 791T/36 | RTA | OS | √ | - | - | [89] |
| B7H3 | 8H9 (scFv) | PE38 | OS | √ | √ | - | [92] |
| 80 kDa sarcoma associated antigen | TP-3 | PAP | OS | √ | √ | - | [94] |
| 80 kDa sarcoma associated antigen | TP-3 (dsFv) TP-3 (dsFv)2 |
PE38 | OS | √ | √ | - | [95] |
| CD133 | AC133 293C |
Saporin | S | √ | √ | - | [98] |
| TEM1 | 78Fc | Saporin | S | √ | √ | - | [99] |
| Endoglin | OMTX003 | Nigrin-b A chain | ES | √ | √ | - | [62] |
The symbols √ and - mean tested and not tested, respectively, in vitro, in vivo or in a clinical trial. Abbreviations: CSPG4, chondroitin sulfate proteoglycan 4; dsFv, disulfide-linked fragment variable; EGFR, epidermal growth factor receptor; ES, Ewing sarcoma; ETA’, truncated version of Pseudomonas exotoxin A; OS, osteosarcoma; PE, Pseudomonas exotoxin; RMS, rhabdomyosarcoma; RTA, ricin toxin A-chain; S, sarcoma (unspecified type); scFv, single-chain fragment variable.